Skip to main content
Erschienen in: Acta Neuropathologica 2/2003

01.08.2003 | Regular Paper

Evaluation of diagnostic NOTCH3 immunostaining in CADASIL

verfasst von: Saskia A. J. Lesnik Oberstein, Sjoerd G. van Duinen, Rivka van den Boom, Marion L. C. Maat-Schieman, Mark A. van Buchem, Hans C. van Houwelingen, Ingrid M. Hegeman-Kleinn, Michel D. Ferrari, Martijn H. Breuning, Joost Haan

Erschienen in: Acta Neuropathologica | Ausgabe 2/2003

Einloggen, um Zugang zu erhalten

Abstract

CADASIL is caused by mutations in the NOTCH3 gene. Although increasingly recognized as a disease entity, the diagnostic confirmation can be lengthy or inconclusive. Recently, NOTCH3 immunostaining of skin biopsy specimens has been introduced as a new diagnostic test. The aim of this study was to independently assess the diagnostic value of NOTCH3 immunostaining, and determine whether the degree of immunostaining correlates with other disease parameters. We determined NOTCH3 mutation carrier status in 62 symptomatic and asymptomatic individuals from 15 CADASIL families. Skin biopsy specimens of these individuals, as well as of a disease control group, were immunostained with NOTCH3 antibody and blindly analyzed by two independent observers to determine sensitivity and specificity. A semiquantitative NOTCH3 immunostaining score was correlated with clinical, genetic and MRI parameters. The sensitivity was 90.2% and 85.4%, respectively, for the two observers, the specificity 95.2% and 100%; both lower than previously reported. Certain NOTCH3 mutations may underlie false-negative results. False-positive results were found in a non-mutated control, and also in one disease control. There was no difference in immunostaining between symptomatic and asymptomatic NOTCH3 mutated individuals. Furthermore, the NOTCH3 immunostaining score did not correlate with clinical or MRI parameters. NOTCH3 immunostaining is a supportive, but not definitive, CADASIL diagnostic test, and should be interpreted in the context of clinical and radiological data. Confirmation by DNA analysis is requisite for positive results, and when there exists high clinical suspicion, also for negative results.
Literatur
1.
Zurück zum Zitat Bergmann M, Ebke M, Yuan Y, Brück W, Mugler M, Schwendemann G (1996) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): a morphological study of a German family. Acta Neuropathol 92:341–350CrossRefPubMed Bergmann M, Ebke M, Yuan Y, Brück W, Mugler M, Schwendemann G (1996) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): a morphological study of a German family. Acta Neuropathol 92:341–350CrossRefPubMed
2.
Zurück zum Zitat Bornebroek M, Haan J, Maat-Schieman ML, Duinen SG van, Roos RA (1996) Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): a review of clinical, radiologic and genetic aspects. Brain Pathol 6:111–114PubMed Bornebroek M, Haan J, Maat-Schieman ML, Duinen SG van, Roos RA (1996) Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): a review of clinical, radiologic and genetic aspects. Brain Pathol 6:111–114PubMed
3.
Zurück zum Zitat Brulin P, Godfraind C, Leteurtre E, Ruchoux MM (2002) Morphometric analysis of ultrastructural vascular changes in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. Acta Neuropathol 104:241–248PubMed Brulin P, Godfraind C, Leteurtre E, Ruchoux MM (2002) Morphometric analysis of ultrastructural vascular changes in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. Acta Neuropathol 104:241–248PubMed
4.
Zurück zum Zitat Davous P (1998) CADASIL: a review with proposed diagnostic criteria. Eur J Neurol 5:219–233CrossRefPubMed Davous P (1998) CADASIL: a review with proposed diagnostic criteria. Eur J Neurol 5:219–233CrossRefPubMed
5.
Zurück zum Zitat Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G, Ebke M, Klockgether T, Gasser T (1998) The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 44:731–739PubMed Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G, Ebke M, Klockgether T, Gasser T (1998) The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 44:731–739PubMed
6.
Zurück zum Zitat Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cécillion M, Maciazek J, Cruaud C, Cabanis E-A, Ruchoux M-M, Weissenbach J, Bach M-A, Bousser M-G, Tournier-Lasserve E (1996) Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383:707–710PubMed Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cécillion M, Maciazek J, Cruaud C, Cabanis E-A, Ruchoux M-M, Weissenbach J, Bach M-A, Bousser M-G, Tournier-Lasserve E (1996) Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383:707–710PubMed
7.
Zurück zum Zitat Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssière C, Cruaud C, Maciazek J, Weissenbach J, Bousser M-G, Bach M-A, Tournier-Lasserve E (1997) Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350:1511–1515PubMed Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssière C, Cruaud C, Maciazek J, Weissenbach J, Bousser M-G, Bach M-A, Tournier-Lasserve E (1997) Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350:1511–1515PubMed
8.
Zurück zum Zitat Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F, Godfrain C, Tournier-Lasserve E (2000) The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 105:597–605PubMed Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F, Godfrain C, Tournier-Lasserve E (2000) The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 105:597–605PubMed
9.
Zurück zum Zitat Joutel A, Favrole P, Labauge P, Chabriat H, Lescoat C, Andreux F, Domenga V, Cecillon M, Vahedi K, Ducros A, Cave-Riant F, Bousser MG, Tournier-Lasserve E (2001) Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet 358:2049–2051CrossRefPubMed Joutel A, Favrole P, Labauge P, Chabriat H, Lescoat C, Andreux F, Domenga V, Cecillon M, Vahedi K, Ducros A, Cave-Riant F, Bousser MG, Tournier-Lasserve E (2001) Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet 358:2049–2051CrossRefPubMed
10.
Zurück zum Zitat Lesnik Oberstein SAJ, Ferrari MD, Bakker E, Gestel J van, Kneppers ALJ, Frants RR, Breuning MH, Haan J (1999) Diagnostic Notch3 sequence analysis in CADASIL: three new mutations in Dutch patients. Neurology 52:1913–1915PubMed Lesnik Oberstein SAJ, Ferrari MD, Bakker E, Gestel J van, Kneppers ALJ, Frants RR, Breuning MH, Haan J (1999) Diagnostic Notch3 sequence analysis in CADASIL: three new mutations in Dutch patients. Neurology 52:1913–1915PubMed
11.
Zurück zum Zitat Lesnik Oberstein SAJ, Boom R van den, Buchem MA van, Houwelingen HC van, Bakker E, Vollebregt E, Ferrari MD, Breuning MH, Haan J (2001) Cerebral microbleeds in CADASIL. Neurology 57:1066–1070PubMed Lesnik Oberstein SAJ, Boom R van den, Buchem MA van, Houwelingen HC van, Bakker E, Vollebregt E, Ferrari MD, Breuning MH, Haan J (2001) Cerebral microbleeds in CADASIL. Neurology 57:1066–1070PubMed
12.
Zurück zum Zitat Ruchoux M-M, Maurage C-A (1997) CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 56:947–964PubMed Ruchoux M-M, Maurage C-A (1997) CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 56:947–964PubMed
13.
Zurück zum Zitat Ruchoux M-M, Chabriat H, Bousser M-G, Baudrimont M, Tournier-Lasserve E (1994) Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke 25:2291–2292PubMed Ruchoux M-M, Chabriat H, Bousser M-G, Baudrimont M, Tournier-Lasserve E (1994) Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke 25:2291–2292PubMed
14.
Zurück zum Zitat Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J (1993) A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114:7–12CrossRefPubMed Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J (1993) A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114:7–12CrossRefPubMed
Metadaten
Titel
Evaluation of diagnostic NOTCH3 immunostaining in CADASIL
verfasst von
Saskia A. J. Lesnik Oberstein
Sjoerd G. van Duinen
Rivka van den Boom
Marion L. C. Maat-Schieman
Mark A. van Buchem
Hans C. van Houwelingen
Ingrid M. Hegeman-Kleinn
Michel D. Ferrari
Martijn H. Breuning
Joost Haan
Publikationsdatum
01.08.2003
Verlag
Springer-Verlag
Erschienen in
Acta Neuropathologica / Ausgabe 2/2003
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-003-0701-6

Weitere Artikel der Ausgabe 2/2003

Acta Neuropathologica 2/2003 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.